SynthesisBMC infectious diseases2025
Prevalence of human brucellosis in Ethiopia: systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Seroprevalence of Brucellosis Among Camels and Camel Owners in Ethiopia: A Systematic Review and Meta-Analysis (2000-2025).Veterinary medicine and science · 2026Pooled it
- High brucellosis prevalence and risk among children aged 5-14 years in Kenyan pastoral health facilities: A facility-based surveillance study.PLoS neglected tropical diseases · 2026Article
- Ultrasensitive Detection and Its Potential Applications in the Diagnosis of Brucellosis.Current microbiology · 2026Review
- Seroprevalence and Associated Factors of Camel and Human Brucellosis in Dire District, Southern Ethiopia: A One-Health Perspective.Veterinary medicine and science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucellosis is a significant public health challenge in Ethiopia, which is characterized by a high prevalence among humans. The disease is primarily transmitted through the consumption of unpasteurized dairy products, direct contact with infected animals, or inhalation of contaminated aerosols. In addition to its impact on human health, brucellosis imposes substantial economic burdens. However, existing epidemiological studies provide inconsistent prevalence estimates, underscoring the need for a more comprehensive and systematic analysis of the disease's burden and associated risk factors in Ethiopia. This systematic review and meta-analysis aimed to generate representative data on the prevalence of human brucellosis in Ethiopia. We searched databases like PubMed and Science Direct for articles published between 2007 and 2022. The analysis included 26 studies covering 5,718 human serum samples. The Complement Fixation Test served as the confirmatory diagnostic test. The results suggest a relatively high seroprevalence of human brucellosis in Ethiopia, with an overall pooled prevalence of 14.0% (95% CI: 10.23, 18.12). Prevalence varied significantly across regions, with the highest observed in Afar (24.21%) and the lowest in Oromia (7.75%). Substantial heterogeneity was observed (I² = 97.64%), suggesting significant variations in prevalence across regions and over time. Additionally, the analysis suggests a possible increasing trend in prevalence over the years. Human brucellosis is a significant health concern in Ethiopia, and further research is crucial for effective prevention and control. The higher prevalence than previously reported in meta-analyses underscores the urgent need for intervention strategies from policymakers, such as the Ministry of Health. Identifying risk factors associated with human brucellosis is essential for implementing effective control measures. Prioritizing brucellosis prevention and control is vital for ensuring public health and well-being. Prospero registration number: CRD42022350237.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.